Cargando…
Comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'
We are writing to communicate our concerns regarding the recently published study by Lees-Shepard et al. (2018).
Autores principales: | Pacifici, Maurizio, Shore, Eileen M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353590/ https://www.ncbi.nlm.nih.gov/pubmed/30698141 http://dx.doi.org/10.7554/eLife.43173 |
Ejemplares similares
-
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity
por: Lees-Shepard, John B, et al.
Publicado: (2018) -
Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'
por: Goldhamer, David J, et al.
Publicado: (2019) -
A Network Pharmacology Study: Reveal the Mechanisms of Palovarotene Against Heterotopic Ossification
por: Huang, Junchao, et al.
Publicado: (2022) -
ACVR1(R206H) FOP mutation alters mechanosensing and tissue stiffness during heterotopic ossification
por: Haupt, Julia, et al.
Publicado: (2019) -
Anti-ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1
por: Aykul, Senem, et al.
Publicado: (2022)